Perspectives of Pediatric Oncologists on Referral for CAR-T Therapy: a Mixed Methods Pilot Study.


Journal

JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827

Informations de publication

Date de publication:
30 Jul 2024
Historique:
received: 15 05 2024
revised: 09 07 2024
accepted: 26 07 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: aheadofprint

Résumé

Receipt of CAR-T at a different institution is a complex, multi-step process; referral by oncologists plays an important role in the process but may be susceptible to bias. Oncologists who previously referred patients for CAR-T at five pediatric hospitals were emailed surveys exploring their CAR-T referral practices. Descriptive statistics were performed, and multivariate analyses examined associations between oncologist characteristics, familiarity with CAR-T, and referral practices. We conducted semi-structured interviews with a subset of participants and used thematic analysis to code transcripts. Sixty-eight oncologists completed the survey, of whom 77% (n = 44) expressed being 'very familiar' with CAR-T. Hispanic oncologists and those at institutions with ≤50 new diagnoses per year were more likely to identify as less familiar with CAR-T (OR 64.3 (CI: 2.45-10452.5), p = 0.04 and OR 24.5 (CI: 3.3-317.3), p = 0.005, respectively). Thirty-eight percent considered non-clinical features (compliance, social support, resources, insurance, language, education, and race or ethnicity) influential in referral decisions. Oncologists who were Hispanic and those practicing for 20+ years were more likely to consider these features significantly influential (OR 14.52 (CI: 1.49-358.66), p = 0.04 and OR 6.76 (CI: 1.18-50.5), p = 0.04). Nine oncologists completed in depth interviews; common themes included barriers and concerns regarding CAR-T referral, the value of an established relationship with CAR-T center, and poor communication after CAR-T. Nearly 40% of oncologists consider non-clinical features significantly influential when deciding to refer patients for CAR-T, raising concern for bias in the referral process. Establishing formal partnerships with CAR-T centers may help address physician barriers in referral.

Sections du résumé

BACKGROUND BACKGROUND
Receipt of CAR-T at a different institution is a complex, multi-step process; referral by oncologists plays an important role in the process but may be susceptible to bias.
METHODS METHODS
Oncologists who previously referred patients for CAR-T at five pediatric hospitals were emailed surveys exploring their CAR-T referral practices. Descriptive statistics were performed, and multivariate analyses examined associations between oncologist characteristics, familiarity with CAR-T, and referral practices. We conducted semi-structured interviews with a subset of participants and used thematic analysis to code transcripts.
RESULTS RESULTS
Sixty-eight oncologists completed the survey, of whom 77% (n = 44) expressed being 'very familiar' with CAR-T. Hispanic oncologists and those at institutions with ≤50 new diagnoses per year were more likely to identify as less familiar with CAR-T (OR 64.3 (CI: 2.45-10452.5), p = 0.04 and OR 24.5 (CI: 3.3-317.3), p = 0.005, respectively). Thirty-eight percent considered non-clinical features (compliance, social support, resources, insurance, language, education, and race or ethnicity) influential in referral decisions. Oncologists who were Hispanic and those practicing for 20+ years were more likely to consider these features significantly influential (OR 14.52 (CI: 1.49-358.66), p = 0.04 and OR 6.76 (CI: 1.18-50.5), p = 0.04). Nine oncologists completed in depth interviews; common themes included barriers and concerns regarding CAR-T referral, the value of an established relationship with CAR-T center, and poor communication after CAR-T.
CONCLUSIONS CONCLUSIONS
Nearly 40% of oncologists consider non-clinical features significantly influential when deciding to refer patients for CAR-T, raising concern for bias in the referral process. Establishing formal partnerships with CAR-T centers may help address physician barriers in referral.

Identifiants

pubmed: 39078720
pii: 7724119
doi: 10.1093/jncics/pkae063
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press.

Auteurs

Anurekha G Hall (AG)

Division of Hematology and Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA, USA.
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Devan M Duenas (DM)

Treuman Katz Center for Pediatric Bioethics and Palliative Care, Seattle Children's Research Institute, Seattle, WA, USA.

Jenna Voutsinas (J)

Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Qian Wu (Q)

Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Adam J Lamble (AJ)

Division of Hematology and Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA, USA.

Elizabeth Gruber (E)

Seattle Children's Therapeutics, USA.

Benjamin Wilfond (B)

Treuman Katz Center for Pediatric Bioethics and Palliative Care, Seattle Children's Research Institute, Seattle, WA, USA.

Julie R Park (JR)

Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.

Anurag K Agrawal (AK)

Division of Hematology and Oncology, UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.

Jonathan M Marron (JM)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Center for Bioethics, Harvard Medical School, Boston, MA, USA.

Classifications MeSH